Amolyt Pharma is a series c plus startup based in France. 2 investors tracked. Status: acquired.
Based in France, Amolyt Pharma is a startup founded in 2017. Amolyt Pharma has been acquired. Brouky records 5 investors associated with the company.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing therapeutic peptides for rare endocrine and metabolic disorders. Its lead program, eneboparatide, is in Phase III trials for hypoparathyroidism, a condition characterized by calcium imbalance and related complications.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.